Tardive Dyskinesia Excellence Forum

Tardive Dyskinesia

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Telephone Visits Not Recommended Telehealth Treatment Medium For TD Evaluation

06/07/2021

Rif El-Mallakh, MD, discusses his study that found that experts feel telephone visits are not adequate for the evaluation of TD and video interviews should be utilized instead to see the patient’s physical health.

Rif El-Mallakh, MD, discusses...

06/07/2021

Psych Congress Network

Videos

Panel Study Investigates the Assessment and Treatment of Tardive Dyskinesia

06/03/2021

Rif El-Mallakh, MD, discusses the methods of his study that sought to learn more about how clinicians diagnose, assess, and manage TD in both in-person and telehealth settings and how TD impacts both patients and their caregivers.

Rif El-Mallakh, MD, discusses...

06/03/2021

Psych Congress Network

Similarities and Differences Between TD Treatments

Videos

04/26/2021

Psych Congress Steering Committee member Rakesh Jain, MD, MPH, explains the similarities and differences between the 2 medications approved by the US Food and Drug Administration for the treatment of tardive dyskinesia.

Psych Congress Steering...

04/26/2021

Psych Congress Network

Videos

Managing the Most Common Side Effects of VMAT2 Inhibitors

04/22/2021

Psych Congress Steering Committee member Rakesh Jain, MD, MPH, answers the question "What are the most common side effects of VMAT2 inhibitors and how can clinicians help patients manage them?"

Psych Congress Steering...

04/22/2021

Psych Congress Network

Videos

Understanding the New TD Treatment Guidelines

04/22/2021

Psych Congress Steering Committee member Rakesh Jain, MD, MPH, discusses recent guidelines on identifying and treating tardive dyskinesia.

Psych Congress Steering...

04/22/2021

Psych Congress Network

Videos

Deutetrabenazine Effective for TD Across Age Groups

10/05/2020

Martha Sajatovic, MD, provides details of a study which found that deutetrabenazine was effective as a treatment for tardive dyskinesia both in patients aged less than 55 years and in patients aged 55 years or older.

Martha Sajatovic, MD, provides...

10/05/2020

Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Tardive Dyskinesia Excellence Forum

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products